Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1343-1349

  Ma, Yu Chao ^a   Li, Cui ^b   Gao, Feng ^a   Xu, Yan ^b   Jiang, Zhi Bin ^a   Liu, Jian Xin ^a   Jin, Long Yu ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Epigallocatechin gallate; Lung cancer

Indexed keywords

CYCLIN D1; EPIGALLOCATECHIN GALLATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CONTROLLED STUDY; CYCLIN D1 GENE; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CATECHIN; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84896704976     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2933     Document Type: Article

References (40)

1. Kanwar J, Taskeen M, Mohammad I, Huo C, Chan TH and Dou QP: Recent advances on tea polyphenols. Front Biosci (Elite Ed) 4: 111-131, 2012.
2. Jin L, Li C, Xu Y, Wang L, Liu J, Wang D, et al: Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol Rep 29: 1983-1990, 2013.
3. Park JS, Khoi PN, Joo YE, Lee YH, Lang SA, Stoeltzing O, et al: EGCG inhibits recepteur d'origine nantais expression by suppressing Egr-1 in gastric cancer cells. Int J Oncol 42: 1120-1126, 2013.
4. Yiannakopoulou EC: Effect of green tea catechins on breast carcinogenesis: a systematic review of in-vitro and in-vivo experimental studies. Eur J Cancer Prev: Aug 9, 2013 (Epub ahead of print).
5. Hagen RM, Chedea VS, Mintoff CP, Bowler E, Morse HR and Ladomery MR: Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells. Int J Oncol 43: 194-200, 2013.
6. Kim SO and Kim MR: (-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity. Int J Oncol 42: 349-358, 2013.
7. Chen H, Landen CN, Li Y, Alvarez RD and Tollefsbol TO: Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J Oncol 2013: 872957, 2013.
8. Kochi T, Shimizu M, Terakura D, Baba A, Ohno T, Kubota M, et al: Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions. Cancer Lett 42: 60-69, 2014.
9. Ogawa K, Hara T, Shimizu M, Nagano J, Ohno T, Hoshi M, et al: (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. Oncol Lett 4: 546-550, 2012.
10. + skin stem cells and skin tumors. Carcinogenesis 34: 1315-1322, 2013.
11. Shimizu M, Adachi S, Masuda M, Kozawa O and Moriwaki H: Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol Nutr Food Res 55: 832-843, 2011.
12. Fujiki H and Suganuma M: Green tea: an effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Lett 324: 119-125, 2012.
13. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
14. Singh BN, Shankar S and Srivastava RK: Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82: 1807-1821, 2011.
15. Han W and Lo HW: Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett 318: 124-134, 2012.
16. Tebbutt N, Pedersen MW and Johns TG: Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 13: 663-673, 2013.
17. Kolch W and Pitt A: Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer 10: 618-629, 2010.
18. Avraham R and Yarden Y: Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12: 104-117, 2011.
19. Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM, et al: Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology 13: 15-20, 1991.
20. Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in cancer. Radiother Oncol 108: 370-377, 2013.
21. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575-589, 2005. (Pubitemid 40799250)
22. Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y and Hung MC: Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 45: 10-17, 2006. (Pubitemid 43122365)
23. Hung LY, Tseng JT, Lee YC, Xia W, Wang YN, Wu ML, et al: Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res 36: 4337-4351, 2008.
24. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, et al: Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280: 31182-31189, 2005. (Pubitemid 41291855)
25. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
26. Katlic MR, Facktor MA, Berry SA, McKinley KE, Bothe A Jr and Steele GD Jr: ProvenCare lung cancer: a multi-institutional improvement collaborative. CA Cancer J Clin 61: 382-396, 2011.
27. Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61: 91-112, 2011.
28. Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med 359: 1367-1380, 2008.
29. Herbst RS, Fukuoka M and Baselga J: Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 4: 956-965, 2004. (Pubitemid 39626219)
30. Janku F, Stewart DJ and Kurzrock R: Targeted therapy in nonsmall-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol 7: 401-414, 2010.
31. Tao Y, Song X, Deng X, Xie D, Lee LM, Liu Y, et al: Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp Cell Res 303: 240-251, 2005. (Pubitemid 40126259)
32. Shi Y, Tao Y, Jiang Y, Xu Y, Yan B, Chen X, et al: Nuclear epidermal growth factor receptor interacts with transcriptional intermediary factor 2 to activate cyclin D1 gene expression triggered by the oncoprotein latent membrane protein 1. Carcinogenesis 33: 1468-1478, 2012.
33. Sato M, Shames DS, Gazdar AF and Minna JD: A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2: 327-343, 2007. (Pubitemid 47181718)
34. Shimizu M, Shirakami Y and Moriwaki H: Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci 9: 1034-1049, 2008. (Pubitemid 351948839)
35. Masuda M, Suzui M and Weinstein IB: Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 7: 4220-4229, 2001. (Pubitemid 34044648)
36. Hou Z, Sang S, You H, Lee MJ, Hong J, Chin KV, et al: Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 65: 8049-8056, 2005. (Pubitemid 41297287)
37. Adachi S, Nagao T, Ingolfsson HI, Maxfield FR, Andersen OS, Kopelovich L, et al: The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 67: 6493-6501, 2007. (Pubitemid 47037535)
38. Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, et al: The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res 15: 4885-4894, 2009.
39. Adachi S, Shimizu M, Shirakami Y, Yamauchi J, Natsume H, Matsushima-Nishiwaki R, et al: (-)-Epigallocatechin gallate downregulates EGF receptor via phosphorylation at Ser1046/1047 by p38 MAPK in colon cancer cells. Carcinogenesis 30: 1544-1552, 2009.
40. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7 (Suppl 4): S31-S39, 2002.